Clinical Trial Update: A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia [Phase 3]

View source ↗

Summary

Phase 3 study comparing zanubrutinib to ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma has completed with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Ibrutinib (ibrutinib)
• Zanubrutinib (zanubrutinib)

Snippet

Sponsor: BeiGene | Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Status: COMPLETED | Results posted: 2023-07-27